Genmab A/S (NASDAQ:GMAB) Sets New 52-Week High - What's Next?

Key Points

• Genmab A/S shares have reached a new 52-week high of $30.40, reflecting strong investor interest with a trading volume of 911,475 shares.
• Equities analysts have varied opinions on Genmab A/S, with several raising their price targets, while the consensus rating is a "Moderate Buy" with an average target price of $40.00.
• The company demonstrated strong financial performance, reporting $0.54 earnings per share for the last quarter, surpassing analyst expectations, with a market capitalization of $19.50 billion.

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Get Free Report) reached a new 52-week high on Tuesday . The company traded as high as $30.40 and last traded at $30.29, with a volume of 911475 shares trading hands. The stock had previously closed at $29.33.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on GMAB shares. HC Wainwright lifted their price target on shares of Genmab A/S from $35.00 to $36.00 and gave the stock a "buy" rating in a research note on Friday, August 15th. Wall Street Zen upgraded Genmab A/S from a "buy" rating to a "strong-buy" rating in a research report on Friday. Truist Financial increased their price target on Genmab A/S from $45.00 to $46.00 and gave the stock a "buy" rating in a report on Tuesday, July 8th. Zacks Research lowered Genmab A/S from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 19th. Finally, Guggenheim raised shares of Genmab A/S from a "neutral" rating to a "buy" rating and set a $43.00 target price for the company in a research note on Tuesday, September 23rd. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Genmab A/S has a consensus rating of "Moderate Buy" and an average target price of $40.00.

Genmab A/S Stock Up 3.6%

The stock has a market capitalization of $19.50 billion, a P/E ratio of 15.26, a P/E/G ratio of 1.70 and a beta of 0.93. The stock's 50 day moving average price is $25.11 and its 200-day moving average price is $22.13.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.54 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.39 by $0.15. The business had revenue of $925.00 million for the quarter, compared to the consensus estimate of $5.77 billion. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%. Genmab A/S has set its FY 2025 guidance at EPS. Analysts anticipate that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current year.

Institutional Investors Weigh In On Genmab A/S

A number of hedge funds and other institutional investors have recently made changes to their positions in GMAB. Osaic Holdings Inc. raised its position in Genmab A/S by 37.8% in the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company's stock worth $33,000 after acquiring an additional 440 shares in the last quarter. Captrust Financial Advisors increased its stake in Genmab A/S by 2.4% in the 2nd quarter. Captrust Financial Advisors now owns 22,442 shares of the company's stock valued at $464,000 after purchasing an additional 526 shares in the last quarter. Rhumbline Advisers boosted its position in Genmab A/S by 3.2% during the first quarter. Rhumbline Advisers now owns 16,956 shares of the company's stock worth $332,000 after purchasing an additional 532 shares in the last quarter. CWM LLC raised its stake in shares of Genmab A/S by 50.5% during the 2nd quarter. CWM LLC now owns 1,797 shares of the company's stock worth $37,000 after buying an additional 603 shares during the last quarter. Finally, Yousif Capital Management LLC increased its holdings in Genmab A/S by 7.8% during the 2nd quarter. Yousif Capital Management LLC now owns 10,943 shares of the company's stock valued at $226,000 after acquiring an additional 790 shares in the last quarter. Institutional investors and hedge funds own 7.07% of the company's stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.